Genzyme Surgical Products
This article was originally published in The Gray Sheet
Executive Summary
Cardiovascular and general surgical biomaterials business receives 510(k) clearance to market the Sepramesh hyaluron-based biosurgical composite for hernia repairs, the company announces March 22. Sepramesh contains a bioresorbable barrier to prevent adhesions common among traditional mesh products. Genzyme plans a roll-out in the second quarter of 2000 targeting the estimated $25 mil. market opportunity among the 64,000 annual U.S. incisional hernia repair procedures